Daré Bioscience, Inc. (DARE)

Daré Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	24.71	15.7	10.48	34.67	51.67
Cash & Short-Term Investments	24.71	15.7	10.48	34.67	51.67
Cash Growth	57.42%	49.85%	-69.78%	-32.91%	1006.64%
Other Receivables	-	-	0.95	1.7	1.15
Total Trade Receivables	-	-	0.95	1.7	1.15
Other Current Assets	2.35	2.75	6.12	6.67	2.48
Total Current Assets	27.06	18.45	17.54	43.04	55.3
Net Property, Plant & Equipment	4.4	2.54	1.98	0.52	0.03
Other Long-Term Assets	1.01	1.11	1.76	0.26	0.49
Total Assets	32.47	22.1	21.28	43.83	55.81
Accounts Payable	1.2	1.46	3.39	2.03	2.1
Accrued Expenses	0.73	3.04	2.89	10.89	3.14
Current Portion of Leases	2.1	0.55	0.47	0.4	0.27
Unearned Revenue	19.65	16.56	13.74	18.3	10.54
Other Current Liabilities	0.01	0	-	-	-
Total Current Liabilities	23.69	21.61	20.48	31.62	16.05
Long-Term Leases	0.56	0.75	0.94	0.09	-
Other Long-Term Liabilities	5.39	5.75	4.91	1	1
Total Long-Term Liabilities	5.95	6.5	5.85	1.09	1
Total Liabilities	29.63	28.11	26.33	32.71	17.05
Common Stock	0	0	0	0.01	0.01
Additional Paid-in Capital	191.95	169.71	166.55	152.53	149.03
Accumulated Other Comprehensive Income	-0.42	-0.43	-0.36	-0.35	-0.15
Retained Earnings	-188.69	-175.29	-171.24	-141.07	-110.13
Shareholders' Equity	2.84	-6.01	-5.05	11.11	38.75
Total Liabilities & Equity	32.47	22.1	21.28	43.83	55.81
Total Debt	2.66	1.3	1.4	0.49	0.27
Net Cash (Debt)	22.06	14.4	9.07	34.18	51.4
Net Cash Growth	53.21%	58.68%	-73.46%	-33.51%	1213.79%
Net Cash Per Share	1.97	1.69	1.25	4.85	10.09
Book Value	2.84	-6.01	-5.05	11.11	38.75
Book Value Per Share	0.25	-0.71	-0.69	1.58	7.60
Tangible Book Value	2.84	-6.01	-5.05	11.11	38.75
Tangible Book Value Per Share	0.25	-0.71	-0.69	1.58	7.60

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q